Recent investigations have focused on the overlap of GLP-1|GIP|GCGR agonist therapies and DA signaling. While GIP activators are increasingly employed for managing type 2 diabetes mellitus, their emerging effects on motivation circuits, specifically influenced by dopaminergic pathways, are attracting significant focus. This paper details a concise